Evidence map›Paper›PMID 37961210›Full record

ArticleResearch square2023

Engineering Tripartite Gene Editing Machinery for Highly Efficient Non-Viral Targeted Genome Integration.

Hangu Nam, Keqiang Xie, Ishita Majumdar, Shaobo Yang, Jakob Starzyk, Danna Lee, Richard Shan, Jiahe Li, Hao Wu

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Hangu NamDepartment of Bioengineering, Northeastern University, Boston, MA 02115, United States.
Keqiang XieFull Circles Therapeutics, INC. 625 Mount Auburn St., Ste. 105, Cambridge, MA 02138, United States.
Ishita MajumdarFull Circles Therapeutics, INC. 625 Mount Auburn St., Ste. 105, Cambridge, MA 02138, United States.
Shaobo YangDepartment of Bioengineering, Northeastern University, Boston, MA 02115, United States.
Jakob StarzykFull Circles Therapeutics, INC. 625 Mount Auburn St., Ste. 105, Cambridge, MA 02138, United States.
Danna LeeFull Circles Therapeutics, INC. 625 Mount Auburn St., Ste. 105, Cambridge, MA 02138, United States.
Richard ShanFull Circles Therapeutics, INC. 625 Mount Auburn St., Ste. 105, Cambridge, MA 02138, United States.
Jiahe LiDepartment of Biomedical Engineering, College of Engineering and School of Medicine, University of Michigan, Ann Arbor, MI 48109, United States.ORCID https://orcid.org/0000-0002-9889-8546
Hao WuFull Circles Therapeutics, INC. 625 Mount Auburn St., Ste. 105, Cambridge, MA 02138, United States.
Full Circle Research (United States) · USNortheastern University · USUniversity of Michigan · US

Funding

Enzymatic and genetic strategies for targeting disease-associated microbial metabolitesDP2GM154019 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jiahe Li · 2023 to 2026
$2.3M
Engineering Probiotics to Sense and Respond to the Intracellular Redox Imbalance towards Mitochondrial DysfunctionR21EB030769 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LI, JIAHE · 2021 to 2021
$611k
A New Class of Chemically Modified Small RNA Inhibitors against Fusobacterium nucleatumR03DE031329 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LI, JIAHE · 2022 to 2023
$341k
NIBIB NIH HHS R21 EB030769NIDCR NIH HHS R03 DE031329NIGMS NIH HHS DP2 GM154019
6 · The paper itself

Abstract

Non-viral DNA donor template has been widely used for targeted genomic integration by homologous recombination (HR). This process has become more efficient with RNA guided endonuclease editor system such as CRISPR/Cas9. Circular single stranded DNA (cssDNA) has been harnessed previously as a genome engineering catalyst (GATALYST) for efficient and safe targeted gene knock-in. Here we developed enGager, a system with enhanced GATALYST associated genome editor, comprising a set of novel genome editors in which the integration efficiency of a circular single-stranded (css) donor DNA is elevated by directly tethering of the cssDNA to a nuclear-localized Cas9 fused with ssDNA binding peptides. Improvements in site-directed genomic integration and expression of a knocked-in DNA encoding GFP were observed at multiple genomic loci in multiple cell lines. The enhancement of integration efficiency, compared to unfused Cas9 editors, ranges from 1.5- to more than 6-fold, with the enhancement most pronounced for transgenes of > 4Kb in length in primary cells. enGager-enhanced genome integration prefers ssDNA donors which, unlike traditional dsDNA donors, are not concatemerized or rearranged prior to and during integration Using an enGager fused to an optimized cssDNA binding peptide, exceptionally efficient, targeted integration of the chimeric antigen receptor (CAR) transgene was achieved in 33% of primary human T cells. Enhanced anti-tumor function of these CAR-T primary cells demonstrated the functional competence of the transgenes. The 'tripartite editors with ssDNA optimized genome engineering' (TESOGENASE

Indexed as

CAR-TCircular single stranded DNACRISPR/Cas9genome integrationhomologous directed repair

Identifiers

PMID37961210
PMCPMC10635301
OpenAlexW4387856026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.